Fluconazole-induced	fluconazole-induced	O	O
torsade	torsade	O	B_disease
de	de	O	B_disease
pointes	pointes	O	I_disease
.	.	O	O

OBJECTIVE	objective	O	O
:	:	O	O
To	to	O	O
present	present	O	O
a	a	O	O
case	case	O	O
of	of	O	O
fluconazole-associated	fluconazole-associated	O	O
torsade	torsade	O	B_disease
de	de	O	B_disease
pointes	pointes	O	I_disease
(	(	O	O
TDP	tdp	O	O
)	)	O	O
and	and	O	O
discuss	discuss	O	O
fluconazole	fluconazole	O	O
's	's	O	O
role	role	O	O
in	in	O	O
causing	causing	O	O
TDP	tdp	O	O
.	.	O	O

CASE	case	O	O
SUMMARY	summary	O	O
:	:	O	O
A	a	O	O
68-year-old	68-year-old	O	O
white	white	O	O
woman	woman	O	O
with	with	O	O
Candida	candida	O	O
glabrata	glabrata	O	O
isolated	isolated	O	O
from	from	O	O
a	a	O	O
presacral	presacral	O	O
abscess	abscess	O	S_disease
developed	developed	O	O
TDP	tdp	O	O
eight	eight	O	O
days	days	O	O
after	after	O	O
commencing	commencing	O	O
oral	oral	O	O
fluconazole	fluconazole	O	O
The	the	O	O
patient	patient	O	O
had	had	O	O
no	no	O	O
other	other	O	O
risk	risk	O	O
factors	factors	O	O
for	for	O	O
TDP	tdp	O	O
,	,	O	O
including	including	O	O
coronary	coronary	O	B_disease
artery	artery	O	B_disease
disease	disease	O	S_disease
,	,	O	O
cardiomyopathy	cardiomyopathy	O	S_disease
,	,	O	O
congestive	congestive	O	B_disease
heart	heart	O	B_disease
failure	failure	O	I_disease
,	,	O	O
and	and	O	O
electrolyte	electrolyte	S_chemicals	O
abnormalities	abnormalities	O	O
There	there	O	O
was	was	O	O
a	a	O	O
temporal	temporal	O	O
association	association	O	O
between	between	O	O
the	the	O	O
initiation	initiation	O	O
of	of	O	O
fluconazole	fluconazole	O	O
and	and	O	O
TDP	tdp	O	O
.	.	O	O

The	the	O	O
TDP	tdp	O	O
resolved	resolved	O	O
when	when	O	O
fluconazole	fluconazole	O	O
was	was	O	O
discontinued	discontinued	O	O
;	;	O	O
however	however	O	O
,	,	O	O
the	the	O	O
patient	patient	O	O
continued	continued	O	O
to	to	O	O
have	have	O	O
premature	premature	O	B_disease
ventricular	ventricular	O	B_disease
contractions	contractions	O	I_disease
and	and	O	O
nonsustained	nonsustained	O	B_disease
ventricular	ventricular	O	B_disease
tachycardia	tachycardia	O	S_disease
(	(	O	O
NSVT	nsvt	O	O
)	)	O	O
until	until	O	O
six	six	O	O
days	days	O	O
after	after	O	O
drug	drug	S_chemicals	O
cessation	cessation	O	O
DISCUSSION	discussion	O	O
:	:	O	O
Use	use	O	O
of	of	O	O
the	the	O	O
Naranjo	naranjo	O	O
probability	probability	O	O
scale	scale	O	O
indicates	indicates	O	O
a	a	O	O
probable	probable	O	O
relationship	relationship	O	O
between	between	O	O
the	the	O	O
use	use	O	O
of	of	O	O
fluconazole	fluconazole	O	O
and	and	O	O
the	the	O	O
development	development	O	O
of	of	O	O
TDP	tdp	O	O
.	.	O	O

The	the	O	O
possible	possible	O	O
mechanism	mechanism	O	O
is	is	O	O
depression	depression	O	O
of	of	O	O
rapidly	rapidly	O	O
activating	activating	O	O
delayed	delayed	O	O
rectifier	rectifier	O	O
potassium	potassium	O	O
currents	currents	O	O
.	.	O	O

In	in	O	O
our	our	O	O
patient	patient	O	O
,	,	O	O
there	there	O	O
was	was	O	O
no	no	O	O
other	other	O	O
etiology	etiology	O	O
identified	identified	O	O
that	that	O	O
could	could	O	O
explain	explain	O	O
QT	qt	O	O
prolongation	prolongation	O	O
or	or	O	O
TDP	tdp	O	O
The	the	O	O
complete	complete	O	O
disappearance	disappearance	O	O
of	of	O	O
NSVT	nsvt	O	O
and	and	O	O
premature	premature	O	B_disease
ventricular	ventricular	O	B_disease
contractions	contractions	O	I_disease
followed	followed	O	O
by	by	O	O
normalization	normalization	O	O
of	of	O	O
QT	qt	O	O
interval	interval	O	O
after	after	O	O
the	the	O	O
drug	drug	S_chemicals	O
was	was	O	O
stopped	stopped	O	O
strongly	strongly	O	O
suggests	suggests	O	O
fluconazole	fluconazole	O	O
as	as	O	O
the	the	O	O
etiology	etiology	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Clinicians	clinicians	O	O
should	should	O	O
be	be	O	O
aware	aware	O	O
that	that	O	O
fluconazole	fluconazole	O	O
,	,	O	O
even	even	O	O
at	at	O	O
low	low	O	O
doses	doses	O	O
,	,	O	O
may	may	O	O
cause	cause	O	O
prolongation	prolongation	O	O
of	of	O	O
the	the	O	O
QT	qt	O	O
interval	interval	O	O
,	,	O	O
leading	leading	O	O
to	to	O	O
TDP	tdp	O	O
.	.	O	O

Serial	serial	O	O
electrocardiographic	electrocardiographic	O	O
monitoring	monitoring	O	O
may	may	O	O
be	be	O	O
considered	considered	O	O
when	when	O	O
fluconazole	fluconazole	O	O
is	is	O	O
administered	administered	O	O
in	in	O	O
patients	patients	O	O
who	who	O	O
are	are	O	O
at	at	O	O
risk	risk	O	O
for	for	O	O
ventricular	ventricular	O	O
arrhythmias	arrhythmias	O	O
.	.	O	O

